Role of contrast-enhanced spectral mammography in the assessment of residual disease following neoadjuvant chemotherapy in patients with breast cancer
Abstract Background Neoadjuvant chemotherapy (NAC) is currently one of the most commonly utilized treatment options for patients with breast cancer. Evaluating residual disease following NAC is vital in post-chemotherapy treatment planning. Underestimation or overestimation of the residual disease m...
Main Authors: | Hebatalla Elkassas, Samar M. El-Maadawy, Sherihan Mahmoud Saad, Amira H. Radwan, Sherihan W. Y. Gareer |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2022-12-01
|
Series: | The Egyptian Journal of Radiology and Nuclear Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43055-022-00935-5 |
Similar Items
-
Contrast-enhanced spectral mammography in the radiological assessment of response to neoadjuvant chemotherapy in breast cancer
by: Anna Grażyńska, et al.
Published: (2021-09-01) -
Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging
by: Valentina Iotti, et al.
Published: (2017-09-01) -
Contrast-Enhanced Spectral Mammography Assessment of Patients Treated with Neoadjuvant Chemotherapy for Breast Cancer
by: Katarzyna Steinhof-Radwańska, et al.
Published: (2021-09-01) -
Contrast-Enhanced Spectral Mammography-Based Radiomics Nomogram for the Prediction of Neoadjuvant Chemotherapy-Insensitive Breast Cancers
by: Zhongyi Wang, et al.
Published: (2021-02-01) -
Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status
by: Hebatalla Elkassas, et al.
Published: (2022-12-01)